Joint Initiative, “Safe Anaesthesia – ASAP,” Is to Improve Anesthesia
Care in Low Resource Countries
IRVINE, Calif. & HONG KONG--(BUSINESS WIRE)--Aug. 29, 2016--
Masimo (NASDAQ:
MASI) announced Sunday at the World Congress of Anaesthesiologists (WCA)
in Hong Kong that it has become the first Global Impact Partner of the World
Federation of Societies of Anaesthesiologists (WFSA). The four-year
partnership, “Safe Anaesthesia – ASAP” (Anesthesia Safety Action Plan),
will initially identify one country with poor access to safe anesthesia,
and will work toward implementing programs and training designed to
improve anesthesia care and safe surgery outcomes.
In 2015, the Lancet Commission on Global Surgery reported that
approximately 5 billion people – the majority of the world’s population
– do not have access to safe, affordable anesthesia and surgical care,
and estimated that 16.9 million die annually as a result.1
These deaths are attributable to a lack of infrastructure, essential
monitoring equipment, and drugs, as well as a shortage of adequately
trained healthcare workers.1
As part of the first phase of the joint project between the WFSA and
Masimo, a high burden country will be identified as the ASAP’s focus.
Key to the project’s success will be bringing together all stakeholders,
including the government, so that infrastructure gaps can be identified,
needs assessed, and the ASAP implemented. Implementation will involve a
combination of training courses and other educational materials,
distribution of essential drugs, and installation of and training on
medical equipment. Training, monitoring, and project assessment will be
ongoing throughout the four years, with an emphasis on ensuring that the
improvements are sustainable.
Lifebox, an NGO (not-for-profit, non-governmental organization)
dedicated to improving safe surgery, will also be assisting with
training support. Kristine Stave, Chief Operating Officer of Lifebox,
commented, “Lifebox works with colleagues on the front line of the
global surgical safety crisis to support long-term improvement in the
safety and quality of anesthesia care. We know firsthand the challenges
of environment, equipment, education – and we also know the
extraordinary capacity for positive change that the best partnerships
can bring. We’re proud to be a part of this urgent and historic
undertaking between the WFSA and Masimo, and to be delivering our shared
goal of making anesthesia safer for millions of patients worldwide.”
WFSA has been uniting anesthesiologists globally for more than 60 years.
With a network of hundreds of thousands of anesthesiologists in more
than 150 countries, WFSA is well positioned to deliver programs that
facilitate learning, and promote the highest standard of anesthesia care
globally. Masimo, whose clinically leading SET® pulse
oximetry is used to monitor over 100 million patients across the world,
has made a commitment to become a WFSA Global Impact Partner in 2016.
Together, WFSA and Masimo created the ASAP action plan, which it is
hoped will become a model for high burden countries to improve
anesthesia care and safe surgery outcomes.
Dr. David Wilkinson, President of the WFSA, stated, “The WFSA is
delighted to announce Masimo as our first Global Impact Partner. We work
together to improve patient care and access to safe anesthesia around
the world.”
Dr Adrian Gelb, Chair of the WFSA’s Safety and Quality Committee and
Professor of Anaesthesia and Perioperative Care at the UCSF School of
Medicine, added, “It is essential that we make safe and affordable
anesthesia and surgical care available to every patient in every
country. Investment in national anesthesia plans, together with key
stakeholders, will ensure that specific country needs are met most
appropriately in order to make the biggest impact.”
“At Masimo, we believe that regardless of where you live or where you
were born, access to quality healthcare that is dignified and safe –
including safe, effective anesthesia and surgery – is a human right, not
a privilege,” said Joe Kiani, Founder and CEO of Masimo. “We are
delighted to be the first partner with the WFSA in bringing much-needed
help, with Safe Anaesthesia – ASAP, to areas of the world blighted by
needless deaths.”
Mr. Kiani added: “The new millennium goal is no longer to provide all of
our people access to health care, but to provide all of our people
access to health care that is systematically safe and dignified.”
@MasimoInnovates |
#Masimo | @0X2020 | @wfsaorg | #WCA2016
Reference
-
Meara JG, Leather AJ, Hagander L et al. Global Surgery 2030: Evidence
and solutions for achieving health, welfare, and economic development. Surgery.
2015 Jul;158(1):3-6.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
success of the ASAP. These forward-looking statements are based on
current expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and many
of which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions with comparable accuracy and unique
advantages, including: immediate and continuous results that enable
earlier treatment without causing invasive trauma in all patients and in
every clinical situation; as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160829006049/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com